Articles2026-05-19T10:34:23+10:00
1505, 2026

NRG1 Fusion Cholangiocarcinoma

By |May 15th, 2026|Categories: All, Treatments & Trials|Tags: |0 Comments

Most patients miss pathways like this, not because they don’t qualify, but because rare fusion signals are never fully investigated in time. NRG1 Fusion Cholangiocarcinoma is now linked to a newly FDA-approved targeted therapy called BIZENGRI for patients carrying this rare fusion pathway.

1505, 2026

NRG1 Fusion Cholangiocarcinoma

By |May 15th, 2026|Categories: All, Treatments & Trials|Tags: |0 Comments

Most patients miss pathways like this, not because they don’t qualify, but because rare fusion signals are never fully investigated in time. NRG1 Fusion Cholangiocarcinoma is now linked to a newly FDA-approved targeted therapy called BIZENGRI for patients carrying this rare fusion pathway.

Go to Top